WindMIL delivers bone marrow-derived lymphocytes

WindMIL Therapeutics Inc. (Baltimore, Md.) emerged from stealth mode to reveal its cell immunotherapy based on bone marrow-derived lymphocytes. The company is evaluating its activated marrow infiltrating lymphocytes (MILs) in a Phase IIb trial alongside other therapies in patients with multiple myeloma.

WindMIL was founded in May 2016 to develop research from the labs of co-founders Ivan Borrello and Kimberly Noonan at The Johns Hopkins University. At its inception, the company raised $11 million in a series A round from Domain Associates, FoxKiser and Silver Rock LLC...